Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT04389632
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- NCT04389632 ↗
- Recruiting
- Seagen, a wholly owned subsidiary of Pfizer
- Focused
We haven't built an HCP commentary report on NCT04389632 (sigvotatug vedotin, pembrolizumab and 2 more in Carcinoma, Non-Small Cell Lung) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT04389632 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Carcinoma, Non-Small Cell Lung; Squamous Cell Carcinoma of Head and Neck; HER2 Negative Breast Neoplasms; Esophageal Squamous Cell Carcinoma; Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Ovarian Neoplasms; Cutaneous Squamous Cell Cancer; Exocrine Pancreatic Adenocarcinoma; Urinary Bladder Neoplasms; Uterine Cervical Neoplasms; Stomach Neoplasms
- Interventions
- sigvotatug vedotin; pembrolizumab; cisplatin; carboplatin
- Arms
- Part A: Dose escalation · Experimental
- Part B: Dose expansion · Experimental
- Part C: sigvotatug vedotin combination therapy in NSCLC, HNSCC, ESCC · Experimental
- Part D: sigvotatug vedotin combination therapy in 1L NSCLC · Experimental
- Part D: sigvotatug vedotin combination therapy in 1L HNSCC · Experimental
- Enrollment
- 1,006 (estimated)
- Primary outcomes
- Number of participants with adverse events (AEs)
- Number of patients with laboratory abnormalities
- Number of participants with dose-limiting toxicities (DLTs)
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
- Start
- Jun 8, 2020
- Primary completion
- Jun 16, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04389632 · updated Jul 6, 2026
Publications
linked from the registry- Lyon RP, Jonas M, Frantz C, Trueblood ES, Yumul R, Westendorf L, Hale CJ, Stilwell JL, Yeddula N, Snead KM, Kumar V, Patilea-Vrana GI, Klussman K, Ryan MC. SGN-B6A: A New Vedotin Antibody-Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications. Mol Cancer Ther. 2023 Dec 1;22(12):1444-1453. doi: 10.1158/1535-7163.MCT-22-0817. PubMed 37619980